Atossa Genetics Inc. (NASDAQ:ATOS) Receives $95.00 Consensus PT from Analysts

Shares of Atossa Genetics Inc. (NASDAQ:ATOS) have earned a consensus recommendation of “Hold” from the five research firms that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $95.00.

Several equities analysts recently issued reports on the company. Ascendiant Capital Markets boosted their price target on Atossa Genetics from $116.25 to $120.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Atossa Genetics in a research note on Wednesday, January 21st.

Atossa Genetics Price Performance

ATOS stock opened at $4.42 on Tuesday. The company has a market cap of $38.06 million, a price-to-earnings ratio of -1.23 and a beta of 1.36. The company has a fifty day moving average price of $8.38 and a 200 day moving average price of $11.16. Atossa Genetics has a 12 month low of $3.76 and a 12 month high of $19.35.

Hedge Funds Weigh In On Atossa Genetics

Several institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC raised its position in Atossa Genetics by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 1,371,909 shares of the company’s stock worth $810,000 after buying an additional 9,627 shares during the last quarter. Hudson Bay Capital Management LP acquired a new position in shares of Atossa Genetics during the second quarter worth about $26,000. Gallagher Capital Advisors LLC purchased a new position in Atossa Genetics during the third quarter worth about $27,000. JPMorgan Chase & Co. lifted its position in Atossa Genetics by 1,294.2% in the third quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock valued at $33,000 after purchasing an additional 35,474 shares during the period. Finally, Bank of America Corp DE lifted its position in Atossa Genetics by 55.7% in the second quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock valued at $83,000 after purchasing an additional 35,629 shares during the period. 12.74% of the stock is owned by institutional investors and hedge funds.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.